ArticleNPJ precision oncology2026
Immunohistochemical biomarker-associated radiomics for classifying thymic epithelial tumors: a multicenter retrospective study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The subtle imaging features of thymic epithelial tumors (TETs), which comprise multiple pathological subtypes of thymoma and thymic carcinoma, are of great significance for the identification of high-risk patients. Finding the radiomics features related to the immunohistochemical markers of TETs may provide a non-invasive method for the construction of a prediction model. This retrospective study analyzed non-enhanced computed tomography (NECT) images of 307 patients with TETs from two institutions. The radiomic features were extracted, clustered, and used to develop the models with machine learning algorithms. In general, the radiomics of TET patients were profiled and clustered into three clusters, which showed differences in correlation between clinicopathological characteristics, including histological type, Masaoka stage, and immunohistochemical results. Moreover, the "original-shape-flatness" and "wavelet-LHL-first-order-Median" were the most strongly correlated with CD117 and TDT expression, and the combined model of the two demonstrated predictive efficacy for CD117/TDT expression and risk groups in training and validation cohorts. This study highlights that radiomics and biomarker-associated features can serve as a non-invasive predictive biomarker for TET patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.